New Drug Clears Abnormal Brain Proteins Tied to Alzheimer's

In people with Alzheimer's disease, a new investigational drug can dramatically reduce the amount of amyloid beta plaque, the tangled clumps of proteins that form in the brains of Alzheimer's patients, according to a new early study of the drug. "We believe that's a hint of efficacy," study co-author Dr. Alfred Sandrock, a neurologist and an executive vice president at Biogen, said during a news briefing. "We believe that needs to be confirmed with further studies." Biogen is the Cambridge, Massachusetts, company that funded the trial and applied to patent the drug.